Iain Dukes - 10 Jun 2022 Form 4 Insider Report for Theseus Pharmaceuticals, Inc. (THRX)

Role
Chairman, Director
Signature
/s/ Bradford Dahms - Attorney-in-Fact
Issuer symbol
THRX
Transactions as of
10 Jun 2022
Transactions value $
$0
Form type
4
Filing time
13 Jun 2022, 20:12:09 UTC
Previous filing
13 Jun 2022
Next filing
28 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction THRX Stock Option (right to buy) Award $0 +30,000 $0.000000 30,000 10 Jun 2022 Common Stock 30,000 $5.75 Direct F1
transaction THRX Stock Option (right to buy) Award $0 +15,000 $0.000000 15,000 10 Jun 2022 Common Stock 15,000 $5.75 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are subject to a service-based vesting requirement, which shall be satisfied on the earlier of (i) June 10, 2023 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service with the issuer on such vesting date.
F2 The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with respect to 1/48th of the shares vesting monthly after June 10, 2022, subject to the Reporting Person's continuous service with the issuer on each such vesting date.